• 
• 
• 
• 

 

"ROLE OF QUETIAPINE IN THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR”

Quetiapine is a drug used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder, sudden episodes of mania or depression associated with bipolar disorder). Quetiapine is known as an anti-psychotic drug (atypical type). It works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain.

This medicine can reduce hallucinations and increase your concentration. This medicine helps you to think more clearly and positively about yourself, overcome nervousness, and become more active in daily life. This drug can also improve your mood, induce deep sleep, increase appetite, and increase energy. Quetiapine can help prevent severe mood swings or decrease how often mood swings occur.

Advances in medical science and technology have made doctors in general and Psychiatrists in particular always provide professional health services. As an effort to improve mental health services during the Covid-19 pandemic, the Indonesian Association of Mental Medicine Specialists (PDSKJI) held a Psychiatry webinar event by Lecturers of the Faculty of Medicine Universitas Sebelas Maret (FK UNS) with Dr. Moerwardi Hospital (RSDM) and the Association of Indonesian Mental Medicine Specialists (PDSKJI) Surakarta with the theme ROLE OF QUETIAPINE IN THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR on Saturday, January 23, 2021, 08.30 to 11.30 Western Indonesian Time which was attended by doctors and colleagues. The speakers in this event were dr. Adriesti Herdaetha, Sp.KJ, M.H with the topic "Medical Ethics", Prof. Dr. dr. Aris Sudiyanto, Sp.KJ (K) with the topic "Role of Quetiapine in Bipolar Disorder Management" and dr. Debree Septiawan, Sp.KJ, M.Kes with the material "Role of Quetiapine in Schizophrenia Management".

FK UNS Lecturer, dr. Rohmaningtyas HS, Sp.KJ, M.Kes, as the Moderator of this webinar said:

"The purpose of the webinar is to increase scientific knowledge in the field of psychiatry, especially the atypical antipsychotic psychopharmacology of quetiapine as a therapeutic option in the management of cases of schizophrenia and bipolar affective disorder. Practical benefit of this practice is the implementation of the latest Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 guidelines and the 2018 International Society for Bipolar Disorders (ISBD), one of the uses of quetiapine as a first-line treatment for bipolar disorder, both manic and depressive episodes."

 

Public Relation of FK UNS: Ari Kusbiyanto
Translator: Wartini